Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Milvexian
Study Locations (20)
California
- Alta Bates Medical Center Cancer Center — Berkeley
- Providence Saint Joseph Medical Center - Cancer Center — Burbank
- Mills Peninsula Health Services — Burlingame
- Sutter Health - Eden Medical Center — Castro Valley
- Neurology Center of North Orange County — Fullerton
- Glendale Adventist Medical Center — Glendale
- UC Irvine Healthcare Center — Irvine
- Sharp Grossmont Hospital — La Mesa
- Long Beach Memorial — Long Beach
- Kaiser Permanente Los Angeles Medical Center — Los Angeles
- Mission Hospital Regional Medical Center — Mission Viejo
- Hoag Memorial Hospital — Newport Beach
- Stanford Stroke Center — Palo Alto
- Kaiser Permanente — Redwood City
- University of California Davis Health System — Sacramento
- Kaiser Permanente — Sacramento
- California Pacific Medical Center — San Francisco
Arizona
- Banner Desert Medical Center — Mesa
- University of Arizona — Tucson
Arkansas
- Plaza Neuroscience Clinic — Fayetteville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15,000 participants |
| Start Date | 2023-02-15 |
| Est. Completion | 2026-12-09 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05702034
The ClinicalTrials.gov registry entry for NCT05702034 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 15,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 442 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Ischemic Stroke; Ischemic Attack, Transient appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05702034 reports 20 study locations spanning 3 distinct geographic areas — top geographies include California, Arizona, Arkansas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05702034 about?
NCT05702034 is a clinical study titled "A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE". The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
What is the current status of trial NCT05702034?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 15,000 participants. The study started on 2023-02-15. Estimated completion is 2026-12-09.
What conditions does trial NCT05702034 study?
This clinical trial studies the following conditions: Ischemic Stroke; Ischemic Attack, Transient. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05702034?
The interventions under investigation include: Placebo (DRUG), Milvexian (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05702034?
This trial is sponsored by Janssen Research & Development, which has 442 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05702034 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.